Isolevuglandins disrupt PU.1-mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus.

Isolevuglandins disrupt PU.1-mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus.
复制标题

DOI:
10.1172/jci.insight.136678
复制
发表时间:
2022-07-08
期刊:
影响因子:
8
通讯作者:
Harrison, David G.
Harrison, David G.
中科院分区:
医学1区
文献类型:
--
作者:
Patrick, David M.;Visitacion, Nestor de la;Krishnan, Jaya;Chen, Wei;Ormseth, Michelle J.;Stein, C. Michael;Davies, Sean S.;Amarnath, Venkataraman;Crofford, Leslie J.;Williams, Jonathan M.;Zhao, Shilin;Smart, Charles D.;Dikalov, Sergey;Dikalova, Anna;Xiao, Liang;Van Beusecum, Justin P.;Ao, Mingfang;Fogo, Agnes B.;Kirabo, Annet;Harrison, David G.

文献摘要

参考文献

相似文献

我们描述了导致系统性红斑狼疮(SLE)的机制。在患有 SLE 的人类和 2 个 SLE 小鼠模型中,单核细胞和树突细胞中的异油甘素加合物(isoLG 加合物)显着富集。我们发现,在易患系统性红斑狼疮的小鼠和患有系统性红斑狼疮的人类中,都形成了针对 isoLG 加合物的抗体。此外,转录因子 PU.1 在关键 DNA 结合位点的 isoLG 连接显着减少了所有 C1q 亚基的转录。用特异性 isoLG 清除剂 2-羟基苄胺 (2-HOBA) 治疗易患 SLE 的小鼠可改善自身免疫参数,包括浆细胞扩增、循环 IgG 水平和抗 dsDNA 抗体滴度。 2-HOBA 还可以降低血压、减轻肾损伤并减少表达 C1q 的树突状细胞中独特的炎症基因表达。因此,isoLG 加合物在 SLE 系统性自身免疫和高血压的发生和维持中发挥重要作用。
We describe a mechanism responsible for systemic lupus erythematosus (SLE). In humans with SLE and in 2 SLE murine models, there was marked enrichment of isolevuglandin-adducted proteins (isoLG adducts) in monocytes and dendritic cells. We found that antibodies formed against isoLG adducts in both SLE-prone mice and humans with SLE. In addition, isoLG ligation of the transcription factor PU.1 at a critical DNA binding site markedly reduced transcription of all C1q subunits. Treatment of SLE-prone mice with the specific isoLG scavenger 2-hydroxybenzylamine (2-HOBA) ameliorated parameters of autoimmunity, including plasma cell expansion, circulating IgG levels, and anti-dsDNA antibody titers. 2-HOBA also lowered blood pressure, attenuated renal injury, and reduced inflammatory gene expression uniquely in C1q-expressing dendritic cells. Thus, isoLG adducts play an essential role in the genesis and maintenance of systemic autoimmunity and hypertension in SLE.
DOI: 10.1084/jem.173.3.763
发表时间: 1991-03-01
期刊: The Journal of experimental medicine
影响因子: --
作者:
Camp RL;Kraus TA;Birkeland ML;Puré E
通讯作者: Puré E
DOI: 10.1084/jem.20050075
发表时间: 2005-05-02
期刊: The Journal of experimental medicine
影响因子: --
作者:
Dakic A;Metcalf D;Di Rago L;Mifsud S;Wu L;Nutt SL
通讯作者: Nutt SL
DOI: 10.1038/s41590-019-0398-x
发表时间: 2019-07-01
期刊: NATURE IMMUNOLOGY
影响因子: 30.5
作者:
Arazi, Arnon;Rao, Deepak A.;Goldman, Daniel H.
通讯作者: Goldman, Daniel H.
DOI: 10.1016/j.chemphyslip.2014.03.002
发表时间: 2014-07
影响因子: 3.4
作者:
Davies SS;Guo L
通讯作者: Guo L
DOI: 10.1081/scc-200048945
发表时间: 2005-01-01
影响因子: 2.1
作者:
Amarnath, V;Amarnath, K;Roberts, LJ
通讯作者: Roberts, LJ